These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 26215952

  • 1. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC.
    J Clin Oncol; 2016 Mar 10; 34(8):794-802. PubMed ID: 26215952
    [Abstract] [Full Text] [Related]

  • 2. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.
    J Clin Oncol; 2016 Mar 01; 34(7):721-30. PubMed ID: 26729443
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
    Shea M, Huberman MS, Costa DB.
    J Thorac Oncol; 2016 Jul 01; 11(7):e81-2. PubMed ID: 26845194
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.
    J Thorac Oncol; 2016 Sep 01; 11(9):1493-502. PubMed ID: 27343443
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ.
    Oncologist; 2016 Apr 01; 21(4):481-6. PubMed ID: 27022036
    [Abstract] [Full Text] [Related]

  • 13. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
    Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y, Zong Y, Zhang S, Li C.
    Int J Clin Oncol; 2019 Sep 01; 24(9):1061-1068. PubMed ID: 31065835
    [Abstract] [Full Text] [Related]

  • 14. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Wong SK, Alex D, Bosdet I, Hughesman C, Karsan A, Yip S, Ho C.
    Lung Cancer; 2021 Apr 01; 154():142-145. PubMed ID: 33667719
    [Abstract] [Full Text] [Related]

  • 15. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.
    Clin Cancer Res; 2019 Feb 15; 25(4):1248-1260. PubMed ID: 30352902
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR.
    J Thorac Oncol; 2017 Aug 15; 12(8):1233-1246. PubMed ID: 28502721
    [Abstract] [Full Text] [Related]

  • 18. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.
    Anticancer Drugs; 2019 Jun 15; 30(5):537-541. PubMed ID: 30762593
    [Abstract] [Full Text] [Related]

  • 19. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
    Rabeau A, Rouquette I, Vantelon JM, Taranchon-Clermont E, Mazières J.
    Rev Mal Respir; 2017 Jan 15; 34(1):57-60. PubMed ID: 27745897
    [Abstract] [Full Text] [Related]

  • 20. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
    Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M.
    Cancer Discov; 2015 Aug 15; 5(8):842-9. PubMed ID: 25971939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.